课题基金 / 基金详情

Development of preventive measures of liver failures caused by HCV infection by clarification of the mechanisms of liver diseases

Development of preventive measures of liver failures caused by HCV infection by clarification of the mechanisms of liver diseases
通过阐明肝病的机制,制定HCV感染引起的肝衰竭的预防措施
批准号:
17013045
负责人:
SHIMOTOHNO Kunitada
金额:
$124.16万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2009

项目摘要

项目成果

SHIMOTOHNO Kunitada的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hepatitis C virus is a major causative agent for development of various liver failures including chronic hepatitis and hepatocellular carcinoma. One of the major problem of the developing such liver failures by HCV is persistent nature of HCV infection. In fact, those of individuals who became free from HCV infection by interferon treatment were cured from HCV associated liver failures thereafter. Thus, the development of efficient anti-HCV agents is one goal to prevent HCV related liver diseases. In addition, clarification of the mechanism of the development of liver failures contributes to establish preventive measures for onset of HCV-related diseases. Aims in this work are, therefore, firstly, to understand detail mechanisms of HCV proliferation to obtain insights of the knowledge to develop anti-HCV agents and, secondary, to reveal the mechanisms of the development of liver failure which contributes to develop measures to prevent exacerbation of liver diseases. In this work, I discovered following evidences; (1) Cyclosporin A inhibited HCV genome replication efficiently through impairing the function of cyclophilins, (2) a new ubiquitin E3 ligase which regulats interferon signaling was discovered, (3) HCV infection dys-regulated lipid metabolism as well as lipid transfer mechanism. And this dys-regulation is important for efficient replication of HCV. (4) Dys-regulation of lipid metabolisms and lipoprotein transfer mechanism may contribute to exacerbate of liver failure and, therefore, regulation of lipid metabolism will be therapeutics for not only prevent liver diseases but also prevent HCV proliferation.
期刊论文(65)
专著(0)
科研奖励(0)
会议论文
蛋白質核酸酵素(c型肝炎ウイルスの増殖戦略)
蛋白核酸酶(丙型肝炎病毒增殖策略)
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [宮成悠介, 臼田信光, 下遠野邦忠]
通讯作者: 下遠野邦忠
DOI: 10.1016/j.bbrc.2006.03.059
发表时间: 2006-05-12
期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子: 3.1
作者: [Goto, K, Watashi, K, Shimotohno, K]
通讯作者: Shimotohno, K
DOI: 10.1128/jvi.80.9.4510-4520.2006
发表时间: 2006-05-01
期刊: JOURNAL OF VIROLOGY
影响因子: 5.4
作者: [Ishii, N, Watashi, K, Shimotohno, K]
通讯作者: Shimotohno, K
DOI: 10.1074/jbc.m806452200
发表时间: 2009-03-13
期刊: JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子: 4.8
作者: [Ujino, Saneyuki, Yamaguchi, Saori, Takaku, Hiroshi]
通讯作者: Takaku, Hiroshi
52
    The role of lipid metabolism on HCV proliferation
    Roles of lipid in HCV production
    • 批准号:
      20390135
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.9万
    • 财政年份:
      2008
    • 负责人:
      SHIMOTOHNO Kunitada
    • 依托单位:
    The roles of Tax encoded by HTLV on cell proliferation
    • 批准号:
      16390135
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.9万
    • 财政年份:
      2004
    • 负责人:
      SHIMOTOHNO Kunitada
    • 依托单位:
    On the development of the system to screen new anti-HCV drugs
    • 批准号:
      13557024
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.9万
    • 财政年份:
      2001
    • 负责人:
      SHIMOTOHNO Kunitada
    • 依托单位:
    海外基金